Evaluation of Immunotherapy Efficiency in Mouse CaO-1 Ovarian Carcinoma Treated by Vaccines Based on Dendritic Cells

Abstract

Injection of dendritic cells, pulsated by tumor lysate or mucin, containing CA 125 antigen, led to a more than 50% inhibition of tumor growth in female CBA mice with transplanted mouse pseudomucinous CaO-1 ovarian carcinoma in comparison with the control. Tumor-associated CA 125 antigen can be used for obtaining dendritic cell vaccines against ovarian malignant tumors. This trend will extend the potentialities of application of antitumor vaccines based on dendritic cells, as clinical use of this technology is limited by the need in patient's tumor material. Mucin, containing Ca 125 antigen, can be isolated from patient's serum or obtained by gene engineering technologies as a recombinant peptide.

Quantitative Regulation of Melanoma Growth in the Host by Tumor-Specific Serpins in Blood Serum is a Main Reason for Inefficient Tumor Treatment

“…However, these results could not be repeated. Subsequent vaccines on the basis of tumor-associated antigens were not that effective (Eggermont et al, 2009;Sitdikova et al, 2009). However, this case shares many common signs with the phenomenon of cure of Ehrlich carcinoma-bearing mice described by us.…”

Cure of Mice with Advanced Ovarian Adenocarcinoma CaO1 by the Serum Blood Proteins

“…All experiments were carried out in accordance with the legal requirements for animal experiments in the Russian Federation and with the official permission of the Research Institute for Experimental Diagnostics and Therapy of Tumors, N. N. Blokhin National Research Center of Oncology. Adenocarcinoma CaO1 is a very aggressive tumor: no spontaneous regression was never recorded when working with this tumor [3].…”

“…Our aim was to document the effect of blocking of the tumor growth by mouse serum obtained 24 h after removal of the primary tumor node. Mouse ovarian adenocarcinoma CaO1 was used as the experimental model; this tumor described by us earlier has common antigenic determinants with mucin of human ovarian carcinoma CA125 [3].…”